These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21572733)

  • 21. Comparison of rim-sparing versus rim-removal techniques in deep lateral wall orbital decompression for Graves' orbitopathy.
    Zhang S; Li Y; Wang Y; Zhong S; Liu X; Huang Y; Fang S; Zhuang A; Sun J; Zhou H; Fan X
    Int J Oral Maxillofac Surg; 2019 Apr; 48(4):461-467. PubMed ID: 30442552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course.
    Jankauskiene J; Jarusaitiene D
    J Ophthalmol; 2017; 2017():4853905. PubMed ID: 29225963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the quality of life in Indian Graves' orbitopathy patients and validation of Hindi version of GO-QOL questionnaire.
    Delampady K; Reddy SVB; Yadav SB
    Indian J Ophthalmol; 2020 Aug; 68(8):1617-1621. PubMed ID: 32709791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of response to transantral orbital decompression in severe Graves' ophthalmopathy.
    Fatourechi V; Bergstralh EJ; Garrity JA; Bartley GB; Beatty CW; Offord KP; Gorman CA
    Mayo Clin Proc; 1994 Sep; 69(9):841-8. PubMed ID: 8065185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
    Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
    Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychosocial morbidity of Graves' orbitopathy.
    Kahaly GJ; Petrak F; Hardt J; Pitz S; Egle UT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):395-402. PubMed ID: 16181231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in patients with thyroid eye disease.
    Bahmani-Kashkouli M; Pakdel F; Astaraki A; Hashemi M; Honarbakhsh Y; Mirarmandehi B; Jam S
    J Ophthalmic Vis Res; 2009 Jul; 4(3):164-8. PubMed ID: 23198067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing quality of life in Taiwanese patients with Graves' ophthalmopathy.
    Lin IC; Lee CC; Liao SL
    J Formos Med Assoc; 2015 Nov; 114(11):1047-54. PubMed ID: 24434244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
    Zeng P; Fan SX; Li ZJ; Peng YY; Hu YX; Xu MT; Wang M
    J Ophthalmol; 2019; 2019():7602419. PubMed ID: 31011452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life in Graves' ophthalmopathy.
    Wiersinga WM
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
    Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
    Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
    Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The influence factors of quality-of-life in patients with thyroid-associated ophthalmopathy].
    Shen L; Zhu H; Li XX; Liu DD; Chen XY; Liu H
    Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):575-582. PubMed ID: 28851197
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term outcomes of orbital fat decompression in Graves' orbitopathy.
    Cheng AM; Wei YH; Tighe S; Sheha H; Liao SL
    Br J Ophthalmol; 2018 Jan; 102(1):69-73. PubMed ID: 28450378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between quality of life, cognition, and thyroid status in Graves' disease.
    Riguetto CM; Neto AM; Tambascia MA; Zantut-Wittmann DE
    Endocrine; 2019 Jan; 63(1):87-93. PubMed ID: 30173328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic orbital decompression for Graves' ophthalmopathy.
    Levy J; Puterman M; Lifshitz T; Marcus M; Segal A; Monos T
    Isr Med Assoc J; 2004 Nov; 6(11):673-6. PubMed ID: 15562804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients.
    Baldeschi L; Wakelkamp IM; Lindeboom R; Prummel MF; Wiersinga WM
    Ophthalmology; 2006 May; 113(5):874-8. PubMed ID: 16530839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective, Randomized, Double-blind, Placebo-controlled Study of Orbital Radiotherapy for Graves' Ophthalmopathy.
    Gorman CA; Garrity JA; Fatourechi V; Bahn RS; Petersen IA; Stafford SL; Earle JD; Forbes GS; Kline RW; Bergstralh EJ; Offord KP; Rademacher DM; Stanley NM; Bartley GB
    Ophthalmology; 2020 Apr; 127(4S):S160-S171. PubMed ID: 32200817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.